CEO, Manalo LLP

Roderick Manlo

Manalo LLP

We provide event driven research services to hedge fund managers and institutional investors that cover select definitive and pre-announced M&A deals, focusing on identifying and analysing the key upside and downside risks to a particular transaction. We primarily analyse $billion+ takeovers or mergers of publicly-traded European targets, but also look at deals globally to assess when there is a key European angle or aspect that can influence the deal outcome.

With over 16 years’ experience in risk arbitrage and investment banking, we specialise in providing research and advisory services on all facets of risk arbitrage, with particular expertise in:

- Cross-Border M&A
- Hostile Takeovers
- Local Takeover Codes
- Antitrust & Competition
- Financial Valuation
- Shareholder Vote Analysis
- Impacts of Precedent Transactions
- Risk Arbitrage Trading Strategies

Event-Driven

<p>Antitrust regulators’ protocols and assessments of mergers differ by jurisdiction and this insight focuses almost exclusively on the international (ex-US) antitrust aspects of Monsanto / Bayer. We analyse the deal’s impact on competition in Europe, China and Latin America, which provides us with a roadmap of how regulators may judge the pending transaction. Our initial analysis introduces the competitive landscape, market share data by region and the high-level regulatory issues. Based on European Commission (EC) antitrust guidelines, we identify the key horizontal and non-horizontal antitrust risks stemming from a merged entity. Separately, in our in-depth report, we also provide assessments of innovation and R&amp;D and analysis of antitrust parallels with 20 precedent transactions and with the pending Dow / DuPont and Syngenta / ChemChina regulatory reviews. Together these shape our view on how the EC will scrutinise the deal and what Monsanto and Bayer need to do to ensure that antitrust approvals can be achieved.</p>

Antitrust regulators’ protocols and assessments of mergers differ by jurisdiction and this insight focuses almost exclusively on the international (ex-US) antitrust aspects of Monsanto / Bayer. We analyse the deal’s impact on competition in Europe, China and Latin America, which provides us with a roadmap of how regulators may judge the pending transaction. Our initial analysis introduces the competitive landscape, market share data by region and the high-level regulatory issues. Based on European Commission (EC) antitrust guidelines, we identify the key horizontal and non-horizontal antitrust risks stemming from a merged entity. Separately, in our in-depth report, we also provide assessments of innovation and R&amp;D and analysis of antitrust parallels with 20 precedent transactions and with the pending Dow / DuPont and Syngenta / ChemChina regulatory reviews. Together these shape our view on how the EC will scrutinise the deal and what Monsanto and Bayer need to do to ensure that antitrust approvals can be achieved.

Monsanto / Bayer: International Antitrust Reviews

Monsanto Co

Monsanto / Bayer: International Antitrust Reviews